Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550
2009-017270-21Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of iniparib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Overall response rate (ORR). Started Feb 2010; status: completed.
02
Drugs
iniparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017270-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017270-21.